SH3PXD2A

Across TCGA pan-cancer cohorts, SH3PXD2A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SH3PXD2A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SH3PXD2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SH3PXD2A is over-expressed in tumor, although a few such as COAD and OV show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where SH3PXD2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3PXD2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.918	<.001	12	view →
LSCC	Female	All	+0.467	<.001	9	view →
PDAC	Female	All	+0.570	<.001	6	view →
LUAD	Male	All	+0.163	<.001	5	view →
COAD	All	All	−0.146	.014	4	view →
OV	All	All	−0.649	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SH3PXD2A–CCRCC

Open the CCRCC breakdown →